Global Macular Degeneration Drugs Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 1941

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.
In 2018, the global Macular Degeneration Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Macular Degeneration Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Macular Degeneration Drugs development in United States, Europe and China.

The key players covered in this study
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan
...

Market segment by Type, the product can be split into
Lucentis
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Other

Market segment by Application, split into
50-60 Years Old
60-70 Years Old
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Macular Degeneration Drugs status, future forecast, growth opportunity, key market and key players.
To present the Macular Degeneration Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Macular Degeneration Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Macular Degeneration Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Lucentis
1.4.3 Eylea
1.4.4 Avastin
1.4.5 Squalamine
1.4.6 Conercept
1.4.7 Lampalizamab
1.4.8 Other
1.5 Market by Application
1.5.1 Global Macular Degeneration Drugs Market Share by Application (2014-2025)
1.5.2 50-60 Years Old
1.5.3 60-70 Years Old
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Macular Degeneration Drugs Market Size
2.2 Macular Degeneration Drugs Growth Trends by Regions
2.2.1 Macular Degeneration Drugs Market Size by Regions (2014-2025)
2.2.2 Macular Degeneration Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Macular Degeneration Drugs Market Size by Manufacturers
3.1.1 Global Macular Degeneration Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Macular Degeneration Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Macular Degeneration Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Macular Degeneration Drugs Key Players Head office and Area Served
3.3 Key Players Macular Degeneration Drugs Product/Solution/Service
3.4 Date of Enter into Macular Degeneration Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Macular Degeneration Drugs Market Size by Type (2014-2019)
4.2 Global Macular Degeneration Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Macular Degeneration Drugs Market Size (2014-2019)
5.2 Macular Degeneration Drugs Key Players in United States
5.3 United States Macular Degeneration Drugs Market Size by Type
5.4 United States Macular Degeneration Drugs Market Size by Application

6 Europe
6.1 Europe Macular Degeneration Drugs Market Size (2014-2019)
6.2 Macular Degeneration Drugs Key Players in Europe
6.3 Europe Macular Degeneration Drugs Market Size by Type
6.4 Europe Macular Degeneration Drugs Market Size by Application

7 China
7.1 China Macular Degeneration Drugs Market Size (2014-2019)
7.2 Macular Degeneration Drugs Key Players in China
7.3 China Macular Degeneration Drugs Market Size by Type
7.4 China Macular Degeneration Drugs Market Size by Application

8 Japan
8.1 Japan Macular Degeneration Drugs Market Size (2014-2019)
8.2 Macular Degeneration Drugs Key Players in Japan
8.3 Japan Macular Degeneration Drugs Market Size by Type
8.4 Japan Macular Degeneration Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Macular Degeneration Drugs Market Size (2014-2019)
9.2 Macular Degeneration Drugs Key Players in Southeast Asia
9.3 Southeast Asia Macular Degeneration Drugs Market Size by Type
9.4 Southeast Asia Macular Degeneration Drugs Market Size by Application

10 India
10.1 India Macular Degeneration Drugs Market Size (2014-2019)
10.2 Macular Degeneration Drugs Key Players in India
10.3 India Macular Degeneration Drugs Market Size by Type
10.4 India Macular Degeneration Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Macular Degeneration Drugs Market Size (2014-2019)
11.2 Macular Degeneration Drugs Key Players in Central & South America
11.3 Central & South America Macular Degeneration Drugs Market Size by Type
11.4 Central & South America Macular Degeneration Drugs Market Size by Application

12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Macular Degeneration Drugs Introduction
12.1.4 Novartis Revenue in Macular Degeneration Drugs Business (2014-2019)
12.1.5 Novartis Recent Development
12.2 Bayer Healthcare
12.2.1 Bayer Healthcare Company Details
12.2.2 Company Description and Business Overview
12.2.3 Macular Degeneration Drugs Introduction
12.2.4 Bayer Healthcare Revenue in Macular Degeneration Drugs Business (2014-2019)
12.2.5 Bayer Healthcare Recent Development
12.3 Roche
12.3.1 Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Macular Degeneration Drugs Introduction
12.3.4 Roche Revenue in Macular Degeneration Drugs Business (2014-2019)
12.3.5 Roche Recent Development
12.4 Neurotech Pharmaceuticals
12.4.1 Neurotech Pharmaceuticals Company Details
12.4.2 Company Description and Business Overview
12.4.3 Macular Degeneration Drugs Introduction
12.4.4 Neurotech Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2014-2019)
12.4.5 Neurotech Pharmaceuticals Recent Development
12.5 Regeneron Pharmaceuticals
12.5.1 Regeneron Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Macular Degeneration Drugs Introduction
12.5.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2014-2019)
12.5.5 Regeneron Pharmaceuticals Recent Development
12.6 Allergan
12.6.1 Allergan Company Details
12.6.2 Company Description and Business Overview
12.6.3 Macular Degeneration Drugs Introduction
12.6.4 Allergan Revenue in Macular Degeneration Drugs Business (2014-2019)
12.6.5 Allergan Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details